|
| Individualized prognostic calculators in the precision oncology era |
|
https://doi.org/10.18632/oncotarget.26581
Jeremy M.G. Taylor, Andrew G. Shuman, and Lauren J. Beesley
|
| 415-416 |
|
| The effects of genomic germline variant reclassification on clinical cancer care |
|
https://doi.org/10.18632/oncotarget.26501
Thomas P. Slavin, Sophia Manjarrez, Colin C. Pritchard, Stacy Gray, and Jeffrey N. Weitzel
|
| 417-423 |
|
| Inhibition of 5lipoxygenase downregulates stemness and kills prostate cancer stem cells by triggering apoptosis via activation of cJun Nterminal kinase |
|
https://doi.org/10.18632/oncotarget.13422
Sivalokanathan Sarveswaran, Nadimpalli R.S. Varma, Shravan Morisetty, and Jagadananda Ghosh
|
| 424-436 |
|
| A singlecenter experience of posttransplant lymphomas involving the central nervous system with a review of current literature |
|
https://doi.org/10.18632/oncotarget.26522
Anju John John Velvet, Shiv Bhutani, Stavros Papachristos, Reena Dwivedi, Michael Picton, Titus Augustine, and Muir Morton
|
| 437-448 |
|
| Imbalanced sphingolipid signaling is maintained as a core proponent of a cancerous phenotype in spite of metabolic pressure and epigenetic drift |
|
https://doi.org/10.18632/oncotarget.26533
Monique M.P. Speirs, Adam C. Swensen, Tsz Y. Chan, Peter M. Jones, John C. Holman, McCall B. Harris, John A. Maschek, James E. Cox, Richard H. Carson, Jonathon T. Hill, Joshua L. Andersen, John T. Prince, and John C. Price
|
| 449-479 |
|
| Fibroblast growth factor receptor 1 FGFR1 as a therapeutic target in adenoid cystic carcinoma of the lacrimal gland |
|
https://doi.org/10.18632/oncotarget.26558
Ravi Doddapaneni, Wensi Tao, Andrea Naranjo, Neda Nikpoor, David T. Tse, and Daniel Pelaez
|
| 480-493 |
|
| Optimal targeting of BCLfamily proteins in head and neck squamous cell carcinoma requires inhibition of both BCLxL and MCL1 |
|
https://doi.org/10.18632/oncotarget.26563
Thomas J. Ow, Cory D. Fulcher, Carlos Thomas, Pilib Ó Broin, Andrea López, Denis E. Reyna, Richard V. Smith, Catherine Sarta, Michael B. Prystowsky, Nicolas F. Schlecht, Bradley A. Schiff, Gregory Rosenblatt, Thomas J. Belbin, Thomas M. Harris, Geoffrey C. Childs, Nicole Kawachi, Chandan Guha, and Evripidis Gavathiotis
|
| 494-510 |
|
| Serum amyloid A predisposes inflammatory tumor microenvironment in triple negative breast cancer |
|
https://doi.org/10.18632/oncotarget.26566
Rosa Mistica C. Ignacio, Carla R. Gibbs, Soohyun Kim, Eun-Sook Lee, Samuel E. Adunyah, and Deok-Soo Son
|
| 511-526 |
|
| Polymorphism of DNA repair genes in breast cancer |
|
https://doi.org/10.18632/oncotarget.26568
Beata Smolarz, Magdalena M. Michalska, Dariusz Samulak, Hanna Romanowicz, and Luiza Wójcik
|
| 527-535 |
|
| A structural model of the immune checkpoint CD160–HVEM complex derived from HDXmass spectrometry and molecular modeling |
|
https://doi.org/10.18632/oncotarget.26570
Katarzyna Kuncewicz, Marta Spodzieja, Adam Sieradzan, Agnieszka Karczyńska, Katarzyna Dąbrowska, Michał Dadlez, Daniel E. Speiser, Laurent Derre, and Sylwia Rodziewicz-Motowidło
|
| 536-550 |
|
| Sustained response of three pediatric BRAFV600E mutated highgrade gliomas to combined BRAF and MEK inhibitor therapy |
|
https://doi.org/10.18632/oncotarget.26560
Stephanie A. Toll, Hung N. Tran, Jennifer Cotter, Alexander R. Judkins, Benita Tamrazi, Jaclyn A Biegel, Girish Dhall, Nathan J. Robison, Kaaren Waters, Palak Patel, Robert Cooper, and Ashley S. Margol
|
| 551-557 |
|
| Correction: Prorenin receptor acts as a potential molecular target for pancreatic ductal adenocarcinoma diagnosis |
|
https://doi.org/10.18632/oncotarget.26597
Arivajiagane Arundhathi, Wen-Han Chuang, Jen-Kun Chen, Shin-E Wang, Yi-Ming Shyr, Jiun-Yu Chen, Wei-Neng Liao, Hsin-Wei Chen, Yi-Min Teng, Chiao-Chih Pai, and Chih-Hong Wang
|
| 558-558 |
